Literature DB >> 17879919

Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation.

Flore Sicre de Fontbrune1, Marie Robin, Raphael Porcher, Catherine Scieux, Régis Peffault de Latour, Christèle Ferry, Vanderson Rocha, Karim Boudjedir, Agnès Devergie, Anne Bergeron, Eliane Gluckman, Elie Azoulay, Jordane Lapalu, Gérard Socié, Patricia Ribaud.   

Abstract

Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17879919     DOI： 10.1086/521912

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  37 in total

1.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

2.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

3.  A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.

Authors:  Jennifer E Schuster; Reagan G Cox; Andrew K Hastings; Kelli L Boyd; Jay Wadia; Zhifeng Chen; Dennis R Burton; R Anthony Williamson; John V Williams
Journal:  J Infect Dis       Date:  2014-05-26       Impact factor: 5.226

4.  Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement.

Authors:  Sachiko Seo; Angela P Campbell; Hu Xie; Jason W Chien; Wendy M Leisenring; Janet A Englund; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2013-01-05       Impact factor: 5.742

5.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Authors:  Davide Corti; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Laurent Perez; Gloria Agatic; Barbara Guarino; Chiara Silacci; Jessica Marcandalli; Benjamin J Marsland; Antonio Piralla; Elena Percivalle; Federica Sallusto; Fausto Baldanti; Antonio Lanzavecchia
Journal:  Nature       Date:  2013-08-18       Impact factor: 49.962

6.  Refinement of estimates of mortality risk using the Radiologic Severity Index in hematologic malignancy patients with respiratory syncytial virus infection.

Authors:  Ajay Sheshadri; Mahtab Karimipour; Erik Vakil; Lara Bashoura; Myrna Godoy; Muhammad H Arain; Scott E Evans; Burton F Dickey; David E Ost; Roy F Chemaly; Saadia A Faiz
Journal:  Transpl Infect Dis       Date:  2019-05-28       Impact factor: 2.228

7.  Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation.

Authors:  Kari Neemann; Alison Freifeld
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

Review 8.  Severe Respiratory Viral Infections: New Evidence and Changing Paradigms.

Authors:  James M Walter; Richard G Wunderink
Journal:  Infect Dis Clin North Am       Date:  2017-07-05       Impact factor: 5.982

9.  Assessment of Drug Resistance during Phase 2b Clinical Trials of Presatovir in Adults Naturally Infected with Respiratory Syncytial Virus.

Authors:  Danielle P Porter; Ying Guo; Jason Perry; David L Gossage; Timothy R Watkins; Jason W Chien; Robert Jordan
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

10.  Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Jharna N Shah; Katia K El Taoum; Ying Jiang; Uday Popat; Chitra Hosing; Gabriela Rondon; Jeffrey J Tarrand; Richard E Champlin; Roy F Chemaly
Journal:  J Antimicrob Chemother       Date:  2013-04-09       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.